Navigation Links
Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
Date:2/3/2009

Intellectual property based on breakthrough research from a team led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Research Centre, Canada.

TOULOUSE, France and ANN ARBOR, Mich., Feb. 3 /PRNewswire/ -- Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced that it has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy. This technology is based on the findings of a study led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre in Canada.

AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body. As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body. Symptoms of severe AVS can include angina and syncope (fainting), and major complications can include heart failure and sudden death. AVS is the most common form of heart valve disease in Western countries, resulting in more than 50,000 aortic valve replacement surgeries each year in the U.S.

In Dr. Tardif's placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of Pharmacology.

"We are very pleased to add this exciting new intellectual property to our growing portfolio of HDL therapies," said Jean-Louis Dasseux, Ph.D.,
'/>"/>

SOURCE Cerenis Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
6. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
7. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
8. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
11. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Md., March 27, 2007--A new study shows that ... the proportion of,cardiovascular disease (CVD) linked to diabetes ... for increased efforts to,prevent diabetes and to aggressively ... diabetes, according to the investigators,from the long-standing Framingham ...
... the year ended 31 December 2006 , Product ... Phase,III study International partnering process to commerialise M6G,underway ... Pharmaceuticals,plc ("CeNeS" or "the Company"), the CNS focused ... the year ended 31 December 2006. , Operational ...
Cached Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
(Date:7/13/2014)... Ticket Down is a reliable source ... For the fifth straight year (and second under the current ... American stadiums this summer. The tournament features eight club teams ... teams are split into two groups of four and upon ... will compete to become champion. One team that has had ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... new type of sensor for people with diabetes is being ... instead of blood, researchers report. Scientists at Brown University ... using artificial saliva. It uses light, metal and a special ... "Everybody knows that diabetics have to prick their fingers to ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... ANGELES, March 20 The newest and largest facility ... demolition by the new owner of the Singita Animal ... 210 Freeway on Little Tujunga Canyon Road. Funny Man ... Hackett co-founded the Singita Animal Sanctuary back in 2003. ...
... 20 Speaker Nancy Pelosi, along with Reps. ... Early Treatment for HIV Act (ETHA) this week with ... released the following statement: "Effective drug treatments have improved ... people living with HIV/AIDS. However, many uninsured, low-income HIV-positive ...
... The expense of raising another child may be driving the ... Doctors around the United States are reporting a sharp increase ... last year, with one noting that many of his clients ... is that the trend is due both to a decreased ...
... CHICAGO, March 20 The following is ... Kloss, AHIMA Chief Executive Officer: "There is not ... as National Coordinator to lead America,s Health Information ... great promise. His selection by President Obama ...
... with cancer of the voice box (larynx) who receive ... presented at the European Society for Medical Oncology,s Symposium ... Larynx cancer is one of the most common head ... deaths reported worldwide each year. , "The risk ...
... Today Dr. Martin Gleave of the Vancouver Prostate Centre in ... prostate cancer (CRCP) during the 24th Annual Congress of the ... we look at the way kidney cancer treatment has changed ... says Dr Gleave, "Targeted therapies may become available". , ...
Cached Medicine News:Health News:Pelosi Statement on Reintroduction of the Early Treatment for HIV Act 2Health News:With the Economy Down, Vasectomy Rates Are Up 2Health News:Castrate resistant prostate cancer: New therapeutic approaches 2
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
ACMI™ Double-J Closed Tip Ureteral Stents feature patented dual durometer thermosensitive Tecoflex® construction for physician ease of placement and patient comfort....
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... for interoperative placement to stent ... construction and continent urinary diversions. ... Intended for one-time use. CAUTION: ... must not remain indwelling more ...
Medicine Products: